Jounce Therapeutics, Inc.
(NASDAQ : JNCE)

( )
JNCE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.91%195.591.2%$518.97m
GILDGilead Sciences, Inc.
-1.10%72.780.9%$459.77m
BIIBBiogen Inc.
-0.76%328.411.3%$384.66m
CELGCelgene Corporation
-0.91%81.831.2%$339.18m
ILMNIllumina, Inc.
-2.57%313.413.5%$297.65m
REGNRegeneron Pharmaceuticals, Inc.
-1.72%377.552.6%$228.49m
ALXNAlexion Pharmaceuticals, Inc.
-0.37%121.492.0%$215.08m
VRTXVertex Pharmaceuticals Incorporated
-2.02%177.651.9%$210.48m
SRPTSarepta Therapeutics, Inc.
0.64%131.3416.4%$171.12m
AAgilent Technologies, Inc.
-0.92%65.631.5%$157.48m
BMRNBioMarin Pharmaceutical Inc.
-0.06%99.454.4%$135.37m
LGNDLigand Pharmaceuticals Incorporated
-1.24%200.0723.3%$115.36m
VKTXViking Therapeutics, Inc.
-1.80%14.200.9%$112.03m
NKTRNektar Therapeutics
0.35%49.085.6%$109.05m
EXASExact Sciences Corporation
-2.16%65.7725.3%$103.02m

Company Profile

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat catcer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharmain in 2013 and is headquartered in Cambridge, MA.